13 Jul 2009 10:10
13 July 2009
Epistem Holdings Plc ("Epistem" or the "Company")
Directors' Shareholdings
Epistem announces that on 27 March 2009 all of its executive Directors agreed to subscribe for £125 per month towards the Company's share investment plan which became effective on the same day. The share investment plan is open to all employees and Directors in the Company.
Under the terms of the share investment plan £125 per month is the maximum that any Director can subscribe for and this amount will be invested in ordinary shares of 1.5p each in the Company at the prevailing market price ("Partnership Shares"). At the same time as each monthly subscription a maximum of two Matching Shares will be acquired on behalf of each participant in the share investment plan for each Partnership Share subscribed for.
Both Partnership and Matching Shares are being acquired monthly on behalf of Directors/employees by Epistem SIP Trustee Limited, the Directors of which are Dr Robert Nolan and John Rylands, both Directors of the Company. All such shares acquired are registered in Natwest Nominees Account 0591248.
Following the implementation of the share investment plan and as a result of the subscription for Partnership Shares and award of Matching Shares the executive Directors have each increased their beneficial interests in the Company by 419 ordinary shares of 1.5p each. These shares were acquired in tranches at the end of March, April, May and July at prices of 358p, 360p, 360p and 355p respectively.
The current beneficial interests of the executive Directors are set out below:
Matthew Walls 6,064 (0.08%)
Dr Catherine Booth 980,419 (13.60%)
Dr Ged Brady 419 (0.00%)
Dr Jeffrey Moore 14,919 (0.21%)
John Rylands 190,317 (2.64%)
In the future the Company will make an announcement detailing the number and price of Partnership Shares and Matching Shares subscribed for / awarded to each Director at the end of each calendar quarter. The next announcement will therefore be made on or around 30 September 2009.
For further details please contact:
Epistem Plc
Matthew Walls, CEO +44 161 606 7258
Piper Jaffray Ltd.
Neil Mackison. / James Steel +44 20 3142 8700
Genedrive (GDR)